A Phase 2 interventional study of edaravone dexborneol in Stroke and Endovascular Thrombectomy, sponsored by Hui-Sheng Chen. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-12.
Sponsored by Hui-Sheng Chen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.
Among the 613 studies in Stroke with a site in China, this one is the 194th largest by enrollment of the 432 interventional ones that give a count, is one of 52 that started in 2021, is one of 31 in phase 2, and was the 237th registered.
8,279 studies on the registry are indexed under Stroke; 2,066 are open to participants now.
Browse Stroke studies →242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in China
Ages 18–80 · Healthy volunteers
Qingdao Central Hospital · Sites in China
Ages 18–75
Beijing Pins Medical Co., Ltd · Sites in China
Ages 18–75
Capital Medical University · Sites in China
Ages 18–80
Capital Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,421 Stroke studies recruiting now, 698 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
613 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 72 · Phase 4 42
First in 2000; this study’s year is marked. 52 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 49 across 6,045 interventional studies indexed under Stroke.
Median enrollment 169 across the 432 interventional studies, 611 across the 180 observational. Of the 211 that completed or were terminated, 31 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 613 have an industry lead sponsor. The 10 most frequent:
Hui-Sheng Chen is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Hui-Sheng Chen has 2 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
69 of the studies in Stroke with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05976152Phase 3Fudan UniversityEffect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER) | 2026-12 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07002476Phase 3Shanghai East HospitalEarly Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion | 2027-03-01 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
Add all 69 to your calendar (.ics) → With an account.
Among the 613 studies in Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received endovascular thrombectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous injections of 0.9% NaCl BID for 12 ±2days.
Drug: edaravone dexborneol
Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 12 ±2days.
Drug: edaravone dexborneol
Drug pages: EdaravoneStudies of EdaravoneEdaravone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DexborneolStudies of DexborneolDexborneol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
Also known as: edaravone deborbeol placebo
Proportion of patients with modified Rankin Score 0 to 2
Proportion of patients with modified Rankin Score 0 to 2
Time frame: Day 90
Proportion of patients with modified Rankin Score 0 to 1
Proportion of patients with modified Rankin Score 0 to 1
Time frame: Day 90
Distribution of modified Rankin Score
Distribution of modified Rankin Score after the treatment
Time frame: Day 90
Changes in National Institute of Health stroke scale (NIHSS)
the minimum and maximum values of NIHSS are 42 and 0, respectively; higher NIHSS mean a worse outcome
Time frame: 24 hours, 48 hours, and 2 weeks
Change in infarct volume
infarct volume is determinted by CT or DWI
Time frame: 1 week
Proportion of symptomatic intracranial hemorrhage (sICH)
sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
Time frame: 48 hours
Proportion of intraparenchymal hemorrhage (PH1 and PH2)
Proportion of PH1 and PH2 within 48 hours after the treatment
Time frame: 48 hours
Proportion of death
death due to any cause
Time frame: Day 90
Plan to share: Yes
No publications or documents are linked to this record.
Ran from Feb 2021 to primary completion in Oct 2022, 19 months.
Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 19 months is below that.
Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Edaravone · Dexborneol
Hui-Sheng Chen